Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hunan Fangsheng Pharmaceutical Co's quarterly market cap
declined
from Sep. 2025 (¥5,256 Mil) to Dec. 2025 (¥4,935 Mil) and
declined
from Dec. 2025 (¥4,935 Mil) to Mar. 2026 (¥4,746 Mil).
Hunan Fangsheng Pharmaceutical Co's annual market cap
declined
from Dec. 2023 (¥4,819 Mil) to Dec. 2024 (¥4,576 Mil) but then
increased
from Dec. 2024 (¥4,576 Mil) to Dec. 2025 (¥4,935 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hunan Fangsheng Pharmaceutical Co's Enterprise Value for Today is ¥4,981 Mil.
Hunan Fangsheng Pharmaceutical Co (SHSE:603998) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hunan Fangsheng Pharmaceutical Co Market Cap Related Terms
Hunan Fangsheng Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Fangsheng Pharmaceutical Co Market Cap Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Fangsheng Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Fangsheng Pharmaceutical Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Fangsheng Pharmaceutical Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Hunan Fangsheng Pharmaceutical Co's Market Cap falls into.
Hunan Fangsheng Pharmaceutical Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Fangsheng Pharmaceutical Co (SHSE:603998) has a Market Cap of ¥4,733 Mil as of Aug. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hunan Fangsheng Pharmaceutical Co and its competitors. According to the industry distribution chart, Hunan Fangsheng Pharmaceutical Co ranks #335 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 32.8%.
Is Hunan Fangsheng Pharmaceutical Co's Market Cap too high?
Hunan Fangsheng Pharmaceutical Co's current Market Cap is ¥4,733 Mil. Based on the distribution chart, Hunan Fangsheng Pharmaceutical Co ranks #335 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hunan Fangsheng Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Fangsheng Pharmaceutical Co's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hunan Fangsheng Pharmaceutical Co ranks #335 out of 1022 companies for Market Cap. This puts Hunan Fangsheng Pharmaceutical Co in the upper half of its industry. The industry median Market Cap is 224.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 224.79, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hunan Fangsheng Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 224.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Fangsheng Pharmaceutical Co's current Market Cap is ¥4,733 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Fangsheng Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Fangsheng Pharmaceutical Co (SHSE:603998) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.06, compared to a current price of ¥10.78 — trading 10.6% below its estimated fair value. The current Market Cap is ¥4,733 Mil. Hunan Fangsheng Pharmaceutical Co's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hunan Fangsheng Pharmaceutical Co (SHSE:603998), the current Market Cap is ¥4,733 Mil as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Fangsheng Pharmaceutical Co (SHSE:603998) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Fangsheng Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥10.78 is trading 10.6% below its estimated GF Value™ of ¥12.06.
GuruFocus considers Hunan Fangsheng Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603998:
Market Cap: ¥4,733 Mil
GF Value™: ¥12.06 vs. price of ¥10.78 (10.6% below fair value)
No single metric tells the full story. See the SHSE:603998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Fangsheng Pharmaceutical Co Ltd is engaged in pharmaceutical business. The company's business scope covers the production and sales of tablets, capsules, granules, oral suspension, powder, suppository, powder-injection, tinctures, spray lotion, small volume injections, and bulk pharmaceutical chemicals. Its product offerings include Cefixime Tablets, Cefpiramide for Injection, Cefprozil Tablets, Fleroxacin Dispersible Tablets, and others.
86GF Score
Get the complete analysis for SHSE:603998
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603998 has been successfully added to your 
